Summary
CARA Chart
These Cara Therapeutics Analysts Are No Longer Bullish: 'We See No Obvious Future Value Drivers'
Shares of Cara Therapeutics Inc CARA tanked in early trading on Thursday, with the Dow shedding more than 100 points.
Why Is Cara Therapeutics (CARA) Stock Down 27% Today?
Cara Therapeutics (NASDAQ: CARA ) stock is falling hard on Thursday after the development-stage biopharmaceutical company announced new data from a clinical trial. This data comes from the company's Part A KOURAGE-1 study.
Cara Therapeutics discontinues study on a neurological condition as drug fails
Cara Therapeutics said on Wednesday it will discontinue a mid-to-late stage study for a neurological condition that causes itching after its experimental drug did not demonstrate a meaningful clinical benefit compared to placebo.
Cara Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| DP Drew Phillips Fortitude Family Office LLC | 127 | $546 | $546.1 | $0.1 | 0.02% |
 Christopher C. Powers Farther Finance Advisors, LLC | 3 | $44.07 | $14.67 | -$29.4 | -66.71% |
| HAS Hayley A. Snell LRI Investments, LLC | 27 | $116 | $116.1 | $0.1 | 0.09% |
 Carmen McClennon WR Wealth Planners, LLC | 20.62 | $230.02 | $6.39 | -$223.63 | -97.22% |
Cara Therapeutics, Inc. (CARA) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Cara Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Christopher A. Posner CEO | NASDAQ (CM) Exchange | 140755307 CUSIP |
| US Country | 10 Employees | - Last Dividend | 31 Dec 2024 Last Split | 31 Jan 2014 IPO Date |
Overview
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company with a primary focus on creating and bringing to market treatments for chronic pruritus. Established in 2004 and situated in Stamford, Connecticut, the company has made significant strides in developing therapeutics that address the unmet medical needs of patients suffering from persistent itching associated with various conditions. Cara Therapeutics has established critical partnerships with leading pharmaceutical companies across the globe, such as Maruishi Pharmaceutical Co., Ltd in Japan, Vifor Fresenius Medical Care Renal Pharma Ltd., and Chong Kun Dang Pharmaceutical Corporation in South Korea, to expand the development, manufacturing, and commercialization of its lead product, KORSUVA (difelikefalin), and its variations for different indications.
Products and Services
- KORSUVA (difelikefalin) Injection
This is Cara Therapeutics' flagship product, developed for the treatment of moderate-to-severe pruritus in adults undergoing hemodialysis due to chronic kidney disease (CKD). By specifically targeting the underlying causes of itch in CKD patients, KORSUVA injection offers a novel approach to managing this debilitating symptom, which is widely prevalent yet underserved in the current therapeutic landscape.
- Oral Difelikefalin
In addition to its intravenous formulation, Cara Therapeutics is also developing an oral version of difelikefalin. This formulation is currently undergoing Phase II/III clinical trials, aiming to offer a treatment solution for chronic pruritus associated with notalgia paresthetica. The success of this formulation could significantly expand the company's market reach, providing patients suffering from pruritus of various etiologies with a much-needed oral medication option.
